Back

Validation of the pathobiological determinants of atherosclerosis in youth risk score in a Norwegian cohort of young adults

1 September 2025 (13:15 - 14:00)
Organised by: Logo
Congress Presentation Part of: Scores (2) Scores ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Ms Benedikte Lutterbey

Oslo (Norway)

7 More presentations in this session

Presentation thumbnail
Leukocyte trajectories and cardiovascular events in individuals with and without carotid plaque: a community cohort study
Doctor J. Yang (Shanghai, CN)
Abstract Slides Video
Presentation thumbnail
Cardiovascular-kidney-metabolic syndrome in korean: a nationwide stage-specific epidemiology and risk of major adverse cardiovascular events
Professor W. Pyun (Seoul, KR)
Abstract Slides Video
Presentation thumbnail
Validation and comparison of SCORE2-Diabetes and ASCVD score in Japanese patients with diabetes without a history of cardiovascular disease
Doctor Y. Nakamura (Tokyo, JP)
Abstract Slides Video
Presentation thumbnail
Epicardial adipose tissue thickness as an early predictor of metabolic syndrome in young women with BMI <30
Doctor A. Erdem (Istanbul, TR)
Abstract Slides Video
Presentation thumbnail
Cardiotoxicity risk assessment using HFA-ICOS score: a cross-sectional analysis of patients with breast cancer undergoing chemotherapy or anti-HER2 therapies in a tertiary care center
Miss L. Paez Zamora (Bogota, CO)
Abstract Slides Video

Access the full session

Session thumbnail
Scores (2)

The Event

Event poster

ESC Congress 2025

1 September 2025 13:15 CET
You may be interested in
thumbnail
Congress Presentation
ASGARD risk scores for long-term, individualized cardiovascular surveillance of low-risk patients with asymptomatic non-severe aortic valve stenosis: development and internal validation
thumbnail
Congress Presentation
Are conventional cardiovascular risk scoring models predictive of coronary plaque progression?
thumbnail
Congress Presentation
Comparison of cardiovascular disease risk assessment tools in primary prevention patients with raised lipoprotein(a)

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources